Abstract: A hybrid solid-state electrolyte layer for use in an electrochemical cell is provided. The hybrid solid-state electrolyte layer includes a polymeric material, a ceramic material, and an interfacial material adhering the polymeric material and the ceramic material. The interfacial material includes a branched copolymer that includes dopamine and a second monomer. The second monomer forms a polymeric moiety in the copolymer that is the same or similar to the polymeric material. In certain variations, the polymeric material defines a polymeric layer, the ceramic material defines a ceramic layer, and the interfacial material defines an interfacial layer that is disposed between the polymeric layer and the ceramic layer. In other variations, the polymeric material defines a polymeric matrix, the ceramic material defines a plurality of ceramic particles dispersed in the polymeric matrix, and the plurality of ceramic particles are coated with the interfacial material.

Abstract: The present invention discloses a nucleic acid molecule for encoding a chimeric antigen receptor targeting CD22 and CD19. The chimeric antigen receptor of the present invention can be used for treatment of CD19+ and CD22+ B-cell hematological tumors, as well as combined treatment with CD19 CAR-T cells or CD22 CAR-T cells.

Abstract: A method for arterial endothelial-enhanced functional T cell generation is provided. In the method, arterial endothelial cells enhance functional T cell generation by promoting the generation of hematopoietic progenitor cells with T-lineage bias. The first stage of T cell differentiation from human pluripotent stem cells (hPSCs) is optimized, and it is found that hPSC-derived autologous arterial endothelial cells increase the T cell potential of hematopoietic progenitor cells. Moreover, the T cells generated by arterial endothelial cell priming share similar function to that of human peripheral blood T cells. hPSC-derived CD19-CAR-T cells have been verified to have tumor-killing effects both in vivo and in vitro. The established hPSC-T differentiation system would provide a valuable resource for chimeric antigen receptor T cell (CAR-T) therapy.